LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

10.52 -2.59

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.34

Máximo

10.76

Indicadores-chave
By Trading Economics
Rendimento	227M
Vendas	139M
P/E Médio do Setor	4.094 49.888
Margem de lucro	163.843
Funcionários	1,796
EBITDA	1.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+54.84% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.9B
Abertura anterior	13.11
Fecho anterior	10.52

Sentimento de Notícias

By Acuity

10%

90%

8 / 344 Ranking em Healthcare

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de jun. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 de jun. de 2026, 23:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 de jun. de 2026, 23:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 de jun. de 2026, 22:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 de jun. de 2026, 20:51 UTC

Ganhos

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 20:09 UTC

Conversa de Mercado

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 de jun. de 2026, 19:36 UTC

Conversa de Mercado

Cattle Climbs as Crude Oil Falls -- Market Talk

9 de jun. de 2026, 19:32 UTC

Conversa de Mercado

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 de jun. de 2026, 19:25 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 de jun. de 2026, 19:00 UTC

Conversa de Mercado

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 de jun. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 de jun. de 2026, 18:47 UTC

Conversa de Mercado

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 de jun. de 2026, 18:37 UTC

Conversa de Mercado

Canada's Cooling Trade With the U.S. -- Market Talk

9 de jun. de 2026, 18:27 UTC

Conversa de Mercado

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 de jun. de 2026, 17:35 UTC

Conversa de Mercado

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 de jun. de 2026, 17:30 UTC

Conversa de Mercado

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 de jun. de 2026, 16:34 UTC

Conversa de Mercado

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

9 de jun. de 2026, 15:28 UTC

Conversa de Mercado

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 de jun. de 2026, 15:25 UTC

Conversa de Mercado

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

54.84% parte superior

Previsão para 12 meses

Média 16.8 USD 54.84%

Máximo 20 USD

Mínimo 13.6 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Sentimento

By Acuity

8 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.